A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.
Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators.
Harbeck N, et al. Among authors: warm m.
Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31.
Breast Cancer Res Treat. 2017.
PMID: 27798749
Free PMC article.
Clinical Trial.